Page Title
Drug Development Pipeline
Back to the Drug Development Pipeline
Reata Pharmaceuticals
Status
DiscontinuedTherapeutic Approach
Restore CFTR Protein
This program aimed to expand the number of therapies designed to fix the defective CFTR protein in people who have the F508del mutation.
Status
No further development in CF is planned at this time.
Sponsor
This program was sponsored by Reata Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More